which were adjusted to drug interactions. This provides physicians with greater flexibility in prescribing CAMZYOS to a broader group of eligible patients, with revised dosing and monitoring.

FDA-approved updates include reduced frequency of required echo monitoring ... under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS PROGRAM. Please see additional ...

Detailed price information for Psyence Biomedical Ltd (PBM-Q) from The Globe and Mail including charting and trades.

UPPSALA, SE / ACCESS Newswire / April 23, 2025 / Senzime (STO:SEZI)(OTCQX:SNZZF) today announced that it has secured an additional system-wide contract with a US healthcare system. The contract includ ...

During a press conference with Donald Trump in the White House Monday, a reporter asked Bukele if he planned to return Garcia ...

The revenue, in the range of the low hundreds of thousands of dollars, relates to the delivery of the INSPIRA ART100 systems, which have been recently installed at a premier U.S. academic medical ...

In a release after the 2025 reconvened session on April 2, Gov. Glenn Youngkin (R) said, "Over the next 30 days, I will review and take final action on the bills and budget amendments that have been ...

Concluding “the valuation pullback, combined with a minimal tariff drama, create appealing conditions for investors seeking ...

FDA-approved updates include reduced frequency of required echo monitoring from ... only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called the CAMZYOS REMS ...

About 10,000 full-time employees at the Department of Health and Human Services will be let go under Kennedy’s plans ... Cuts will fall heaviest on the Food and Drug Administration, with about 3,500 ...

The decision is based on advice from the Pharmacovigilance Risk Assessment Committee (PRAC) of the EMA, and if a drug is authorized under additional monitoring, the MAH is specifically required to ...

The U.S. Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...